Mandate

Vinge advises SCA in connection with the financing for the acquisition of BSN Medical from EQT

December 21, 2016

Vinge has advised SCA in the negotiations with the banks regarding financing in connection with SCA’s acquisition of the German company BSN Medical, a leading medico technical company, from EQT.

BSN Medical develops, manufactures, markets and sells products within treatment of wounds, compression treatment and orthopaedics. The enterprise value amounts to EUR 2 740 000 000 (based on an estimated net debt as per 31 December 2016). The acquisition will be completely loan-financed and SCA has a binding credit assurance available. Clifford Chance in Germany represented SCA in relation to the acquisition and the banks were represented by Clifford Chance in London.

The transaction is conditional upon the salient regulatory approvals and is expected to be completed during the second quarter of 2017. The financial conditions governing the transaction have not been made public.
 
Vinge’s team consisted of Mikael Ståhl, Helena Håkansson and Lionardo Ojeda.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025